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Abstract
Background: Anthracycline agents are known to be effective in treating tumors and 
hematological malignancies. Although these agents improve survival, their use is associated 
with cardiotoxic effects, which most commonly manifests as left ventricular systolic 
dysfunction (LVSD). As such, guidelines recommend the periodic assessment of left 
ventricular ejection fraction (LVEF). However, as diastolic dysfunction likely proceeds systolic 
impairment in this setting, the role of Tei index may offer additional benefit in detecting 
subclinical LVSD.
Methods: We conducted a systematic review to investigate the evidence for the use of Tei 
index in assessing subclinical cardiotoxicity in patients receiving anticancer agents. A search 
of Medline and EMBASE was performed and relevant studies were reviewed and narratively 
synthesized.
Results: A total of 13 studies were included with a total of 800 patients (mean age range 
46–62 years, percentage of male participants ranged from 0–86.9%). An increase in Tei 
index was observed in 11 studies, which suggested a decline in cardiac function following 
chemotherapy. Out of these, six studies indicated that the Tei index is a useful parameter in 
predicting cardiotoxic LVSD. Furthermore, five studies indicated Tei index to be superior to 
LVEF in detecting subclinical cardiotoxicity.
Conclusions: Though there are some studies that suggest that Tei index may be a useful 
indicator in assessing subclinical anthracycline-related cardiotoxicity, the findings are 
inconsistent and so more studies are needed before the evaluation of Tei index is 
performed routinely in patients receiving chemotherapy.
Introduction
Anthracycline agents are known to be effective in 
treating solid tumors and hematological malignancies 
(1). They are commonly used in clinical practice with 
reported usage rates of 32% of breast cancer patients 
(2) and 57–70% of elderly lymphoma patients in other 
studies (3, 4). Although these treatments have led to 
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improved survival rates in cancer patients, their side 
effects are known to increase morbidity and mortality 
either via cardiotoxicity or the accelerated development 
of cardiovascular disease (5). Cardiotoxicity ultimately 
impacts myocardial structure and function which 
can manifest as cardiac arrhythmias, myo-pericarditis 
or stress cardiomyopathiesn (5). The most common 
anthracycline cardiotoxic side effect includes left 
ventricular systolic dysfunction (LVSD) which is 
thought to affect approximately one-third of all patients 
exposed to chemotherapy treatments (6). Subclinical 
cardiotoxicity is a major cause of concern because it 
may justify switching to alternative or discontinuing 
cancer treatments to minimize long-term damage to the 
myocardium (7).
Transthoracic echocardiography (TTE) allows for 
repeated and standardized assessments of the myocardium 
and is the imaging modality of choice for chemotherapy 
patients due to its wide availability, low cost and relatively 
high reproducibility (8). International guidelines provide 
robust assessment criteria for assessing subclinical 
cardiotoxicity which includes a heavy reliance on 2D 
left ventricular ejection fraction (LVEF) along with the 
more recent inclusion of global longitudinal strain (GLS) 
and 3D-LVEF (7). At present, subclinical cardiotoxicity 
is defined by (1) >10% points decrease to a value below 
the lower limits of normal of LVEF or (2) >15% relative 
percentage reduction from baseline GLS (7). However, a 
reduction in LVEF is a relatively late expression of LVSD 
(9). Furthermore, LVEF is affected by inter-observer 
variability, reliance on optimal 2D images and geometric 
assumptions (10). In addition, subclinical cardiotoxicity is 
thought to begin with changes in left ventricular diastolic 
function with subsequent progression onto LVSD (11). 
Therefore, an assessment tool such as Tei index may 
enable subclinical cardiotoxicity to be detected prior to 
a deterioration in LVEF. Tei index is advantageous as it 
incorporates both systolic and diastolic timing intervals 
(13, 14). Tei index is a numeric value derived from the 
sum of isovolumetric contraction and isovolumetric 
relaxation divided by total ejection time (Fig. 1) which 
can be calculated for both left and right ventricular 
myocardial performance (13, 14). It is advantageous as it 
can be assessed by Pulse Wave Doppler and Tissue Doppler 
echocardiography (Fig. 2). Furthermore, several studies 
have indicated that Tei index is independent of heart rate 
(although several measurements are advised with irregular 
heart rhythms), preload and afterload (12) making Tei 
index an easy parameter to assess overall myocardial 
performance which is accepted in many clinical settings.
The role of Tei index in the detection of subclinical 
cardiotoxicity is currently controversial, with studies 
both in support (14, 15) and against (16) its use. To better 
understand the role of Tei index in the detection of 
Figure 1
Schematic representation of Tei index.
Figure 2
Tei index using Pulse Wave Doppler and Tissue Doppler 
echocardiography. (A) Tissue Doppler imaging of the septal mitral valve 
annulus in the apical 4 chamber. A is measured between the end of late 
diastolic myocardial velocity (A′) to the onset of early diastolic 
myocardial velocity E′. B is the time interval of the entire systolic 
myocardial velocity (S′). All intervals measured outer edge to outer edge 
of the respective defections. (B) Pulse wave Doppler imaging at the 
midpoint between the left ventricular outflow tract and mitral valve in a 
modified apical 4/5 chamber view. a is measured from the termination 
of the mitral inflow active filling wave (A) to the onset of early mitral 
inflow (E). b is measured from the initial to termination deflection of left 
ventricular outflow tract (LVOT). All intervals measured outer edge to 
outer edge of the respective defections.
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subclinical cardiotoxicity in patients who have received 
anthracycline chemotherapy, we conducted a systematic 
review of the literature.
Methods
We conducted a systematic review to evaluate the role of 
Tei index in assessing for subclinical LVSD cardiotoxicity 
in patients receiving anticancer agents. Inclusion criteria 
included: ≥16 years of age, use of anthracycline or 
derivatives as part of the patient’s treatment regimen and 
left ventricular systolic function at baseline and follow-up. 
Exclusion criteria included: conference abstracts, review 
articles, editorial pieces, cases studies, animal studies, 
cardiotoxicity not assessed in cancer patients, studies 
assessing right ventricular Tei index only, assessment 
of interventions in the prevention of cardiotoxicity, 
cardiotoxicity occurring >5 years post-therapy and 
studies which also included radiotherapy as part of the 
patient’s treatment. Tei index was defined as depicted in 
Fig. 1. Studies assessing Tei index by Pulsed wave Doppler 
imaging or Tissue Doppler imaging were included as 
sensitivity of both methods are comparable (9).
A search of MEDLINE and EMBASE was undertaken 
on OVID using the search terms 'Tei index' 'myocardial 
performance' 'cancer' 'leukemia' 'leukaemia' 'lymphoma' 
'chemotherapy' 'cardiotoxicity' and 'anthracyclines' 
in November 2020. The subsequent results were 
independently reviewed for inclusion by two reviewers 
(S B and C S K). Full text of potentially relevant studies 
were obtained and reviewed prior to final inclusion. Data 
extraction was performed by two independent reviewers 
(S B and C S K). For each study the following was extracted: 
study design, year, country of study performed, number of 
participants, mean age of participants, percentage of male 
participants, definition of cardiotoxicity, chemotherapy 
type and Tei index findings. All included studies were 
evaluated in accordance with the Newcastle Ottawa scale. 
The results of the extractions are presented in table with 
results narratively synthesized also.
Results
Our search yielded 212 potentially relevant studies. After 
a detailed review of titles, abstracts, and subsequently full 
articles for potentially relevant studies, 13 studies (1, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 30) were identified 
and included in the final review (Fig. 3).
The description of the studies and the patient 
characteristics are shown in Table 1. A total of 800 patients 
from ten prospective and three retrospective cohort studies 
were included. The number of participants in each study 
ranged from 23 to 100 with a mean age range of 46.1 to 
61.1 years. Male gender distribution varied from 0 to 86.9%. 
Figure 3
Flow diagram of study selection.
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The studies included a variety of chemotherapy protocols 
as shown in Table 1. Breast cancer was the most common 
cancer type included in the studies, however, a variety of 
other cancers were also included (Table 1). Table 2 shows 
the quality assessment of the included studies using the 
Newcastle Ottawa scale. In general, all studies had patients 
with cancer receiving chemotherapy and measures were 
taken to ensure that LVSD was not present at the start. 
However, all the studies did not report adjusted outcomes 
so no stars could be assigned for comparability. Five of 
the included studies had reliable elements in the outcome 
domain for outcome ascertainment, follow-up and low 
degree of missing data but another five studies did not 
report outcomes. Clinical outcomes were clearly defined 
in seven of the included studies (1, 15, 19, 20, 21, 24, 30). 
Although there was a considerable variation in the criteria 
used to define the presence of cardiotoxicity all seven 
studies incorporated a reduction in baseline LVEF by ≥10% 
with and/or without the presence of symptoms.
The Tei index results for the included studies 
are shown in Table 3 with the most pertinent data 
highlighted in bold italics. Eleven studies showed 
an increase in Tei index values between baseline and 
follow-up with increased Tei index values at follow-up 
ranging from 0.41 ± 0.12 (15) to 0.66 ± 0.18 (24). Six 
of these studies (14, 15, 19, 21, 22, 30) indicated that 
a significant increase in Tei index at follow-up was 
a sensitive marker in the prediction of subclinical 
LVSD, in these studies Tei index at follow-up ranged 
from 0.41 ± 0.08 to 0.61 ± 0.10. Furthermore, when 
compared to LVEF, Tei index was superior in predicting 
subclinical cardiotoxic events with five studies (14, 
15, 21, 22, 30) reporting an increased Tei index in 
the presence of a normal LVEF. Only three studies 
concluded Tei index not to be useful in predicting 
cardiotoxicity and that LVEF remained superior (16, 
23, 24).
 Only two of the 13 included studies reported Tei 
index in the relation to patients who went onto develop 
cardiotoxicity compared to those who did not (21, 24). 
Shaikh   et  al. reported no significant difference in Tei 
index at baseline in either of these groups (0.59 ± 0.14 
vs 0.55 ± 0.17, P = 0.31). However, at follow-up, Tei index 
was significantly higher in the cardiotoxicity group 
compared to the non-cardiotoxicity group (0.66 ± 0.18 
vs 0.59 ± 0.17, P = 0.03) (25). Erdogan   et  al. reported 
that Tei index in cardiotoxicity group was significantly 
higher than in the non-cardiotoxicity group (0.47 ± 0.07 
vs 0.41 ± 0.08, P = <0.05. OR: 3.24, 95% CI 1.40–4.1, 
P = 0.02) (22).
Discussion
This first systematic review of Tei index in the 
evaluation of subclinical cardiotoxicity has several key 
findings. First, patients who received chemotherapy 
appear to have increased Tei index post chemotherapy 
which suggests that chemotherapy is associated with 
a reduction in cardiac function. Secondly, only five 
studies have attempted to correlate Tei index with 
LVEF and it remains unclear if Tei index is equivalent, 
better or worse in identifying subclinical cardiotoxic 
LVSD. Thirdly, most of the studies to date are small and 
underpowered to evaluate cardiotoxicity. These findings 
suggest that there is the need for future larger studies to 
incorporate Tei index for the evaluation of subclinical 
cardiotoxic LVSD and whether Tei index is a tool fit for 
clinical practice.
The most common mechanisms of action of 
anthracycline-induced cardiotoxicity is thought to be 
multifactorial and likely encompass the generation 
of reactive oxygen species and inhibition of Top2β in 
cardiomyocytes (7). The effects of these mechanisms 
are thought to be similar to other cardiac pathologies 
whereby diastolic dysfunction precedes the development 
of systolic dysfunction (25, 26, 27, 28). Furthermore, it 
has been shown that the use of anthracyclines agents 
cause an increase in isovolumetric contraction time 
contributing to diastolic dysfunction (26). This may 
explain why an increased Tei index occurred without a 
corresponding decrease in LVEF in a number of studies 
including Ergodan  et al. where an increase in Tei index 
(0.41 ± 0.08) was associated with a three-fold increase 
in the odds of cardiomyopathy while no difference was 
observed for LVEF with it remaining within normal limits 
at a reported 61.7 ± 4.6 (21).
For the detection of anthracycline-induced 
cardiotoxic LVSD, current clinical practice suggests 
routine TTE for LVEF assessment (7). However, limitations 
of TTE include the requirement of high quality 2D images 
to ensure that subtle changes in LVEF by Simpson’s 
biplane can be detected. Furthermore, this method is 
detrimentally affected by intra-observer variation, loading 
conditions and geometric assumptions (9). Tei index has 
an advantage over LVEF because high quality 2D images 
are not essential. In addition, Tei index is independent 
of loading conditions, heart rate variations and geometric 
assumptions (28). Further work is needed to determine 
the optimal 'cutoffs' for abnormal Tei index when LVEF 
is within normal limits for the detection of subclinical 
cardiotoxicity.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://erp.bioscientifica.com © 2020 The authors
 Published by Bioscientifica Ltdhttps://doi.org/10.1530/ERP-20-0013
Downloaded from Bioscientifica.com at 06/02/2021 11:22:00AM
via free access
S Bennett et al. Tei index and the assessment 
for anthracycline cardiotoxicity
R78:1
The incorporation of GLS has greatly enhanced TTE’s 
ability to detect subclinical LVSD prior to a detectable 
deterioration in LVEF (29). From the included studies in 
this review, only two studies incorporated the use of GLS 
(18, 24). However, neither of these directly compared 
Tei index and GLS in the detection of subclinical 
cardiotoxicity. In Dogru  et al., a significant deterioration 
in GLS post chemotherapy was only observed in the 
subgroup of patients with diagnosed lymphoma (GLS 
pre-therapy: −16.7 ± 2.8 vs GLS post-therapy: −14.6 ± 3.3, 
Table 2 Study quality assessment using Newcastle-Ottawa Score for Cohort studies.
 







Ayhan 2012 (14) Not stated *** – ** Fair quality
Belham 2007 (15) Mild (decrease in LVEF >10% from 
baseline with a final LVEF >50%)
Moderate (a decrease in LVEF >10% 
from baseline with a final LVEF <50% 
and no symptoms or signs of heart 
failure)
Severe (decrease in LVEF >10% from 
baseline with a final LVEF <50% and 
symptoms or signs of heart failure or a 
decrease in LVEF of any percentage 
leading to a final LVEF <40% irrespective 
of symptoms or signs of heart failure 
*** * *** Good quality
DiLisi 2011 (17) Not stated *** – ** Fair quality
Dodos 2008 (1) Absolute decline of >20% in LVEF from 
baseline, a decline in absolute valve 
>10% in LVEF from baseline to <55% or 
the occurrence of congestive heart 
failure
*** – *** Good quality
Dogru 2013 (18) Not stated *** – ** Fair quality
Elalouani 2012 (19) Minimal: decrease in LVEF >10% but FE 
remains >50%
Moderate: asymptomatic decrease in 
LVEF >10% with EF <50%.
Severe: heart failure symptoms with a 
decrease in LVEF >10% with EF <50% or 
final LVEF <40%
*** – ** Fair quality
Elbl 2006 (20) Not stated ** – ** Poor quality
Erdogan 2011 (21) Baseline LVEF decreased by ≥20% to a 
final value of 50% or by ≥10% to <50% 
and / or who exhibited clinical evidence 
of congestive heart failure. Based on 
previous studies but not ESC.
*** – *** Good quality
Mizia-Stec 2013 (22) Not stated *** – ** Fair quality
Rohde 2007 (16) Not stated ** – – Poor quality
Senju 2007 (23) Not stated *** – * Poor quality
Shaikh 2016 (24) Clinical HF (diagnosed by Cardiologost) 
with a reduction in LVEF ≥5% to 
absolute value <55% or an 
asymptomatic reduction of LVEF of >0% 
to <55% based on Cardaci review and 
evaluation committee
*** – *** Good quality
Zhang 2017 (30) 
 
Relative reduction in LVEF ≥10%  
from baseline or absolute LVEF  
value <50% after therapy – based  
on ESC position paper
*** – *** Good quality 
 
aSelection domain based on: (1) representativeness of exposed cohort, (2) selection of the non-exposed cohort, (3) ascertainment of exposure, (4) 
demonstration that outcome of interest was not present at the start of the study, a maximum of four stars can be awarded for this domain. bComparability 
domain based on: comparability of cohorts on the basis of the design of analysis – *control for age, **control for other factors. cOutcome domain based 
on: (1) assessment of outcome, (2) was follow-up long enough for outcomes to occur, (3) adequacy of follow-up of cohorts. A star (*) is awarded for each of 
the criteria meet, maximum score of 9 is attainable.
LVEF, Left ventricular ejection fraction.
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Table 3 Tei index evaluation and outcomes, most pertinent data highlighted in bold italics.
Study ID Reference
 
Timing of Tei index 
assessment
Tei index findings and comparison 








Ayhan 2012 (14) Mean 5 months after 
last cycle of 
chemotherapy
Tei index at:
0 months: 0.56 ± 0.11
Follow-up: 0.61 ± 0.10, P = 0.001
No significant change in LVEF (no 
data given)




Tei index increases at 
follow-up compared to 
start of chemotherapy
Tei index was a more 
useful indicator of 
cardiotoxicity
Belham 2007 (15) 1 to 3 months after 
completion of 
chemotherapy
Tei index pre vs post: 0.41 ± 0.12 
vs 0.51 ± 0.16, P < 0.0001
LVEF (%) pre vs post: 63.9 ± vs 
59.1 ± 7.0 
2/51 developed severe 
cardiotoxicity, 2/51 
moderate cardiotoxicity 
and 9/51 mild 
cardiotoxicity; no 
results according to Tei 
index
Tei index is useful to 
detect chemotherapy-
induced deteriorations in 
left ventricular function 
with more statistical 
significance than LVEF or 
other echocardiographic 
parameter
DiLisi 2011 (17) 0, 3 and 6 months 
after chemotherapy
Tei index at:
0 months: 0.36 ± 0.09
3 months: 0.43 ± 0.08, P < 0.05
6 months: 0.45 ± 0.08, P < 0.05
LVEF (%) at:
0 months: 62 ± 5
3 and 6 months: 61 ± 3, P > 0.05
Not reported Tei index increases at 3 
and 6 months compared 
to start of chemotherapy 
treatment
Tei index did not correlate 
with deterioration in 
ejection fraction
Dodos 2008 (1) 0 months, 
immediately 
following 
chemotherapy, 1, 6 
and 12 months
Tei index at:
0 months: 0.36 ± 0.01.
Immediately post chemotherapy: 
0.37 ± 0.01, P = 0.214
1 month: 0.43 ± 0.01, P ≤ 0.00001
6 and 12 months: states 
remained elevated, but no 
values stated (no P value)
LVEF (%) at:
0 months: 65.9 ± 0.6%, range 55–83
Immediately following 
chemotherapy: significant drop 
in LVEF (no values given)
6 and 12 months: Remained 
within normal limits but no 
values or P values given
0/85 patients developed 
clinical signs or 
symptoms of heart 
failure
Tei index increases at 1, 6 
and 12 months compared 
to start of chemotherapy 
treatment. Tei index did 
not correlate with 
deterioration in ejection 
fraction
Dogru 2013 (18) 0 and 1 months Tei index significantly increased 
from baseline to 1 month, 
P = 0.001 but no values stated 
Not reported Tei index increases at 1 
month compared to 
start of chemotherapy 
treatment
Elalouani 2012 (19) 0 months, during and 
end of chemotherapy 
treatment
Tei index at:
0 months: 0.29 (0.22–0.39)
During chemotherapy: 0.42 
(0.29–0.53)
End of chemotherapy: 0.57 
(0.29–0.61)
LVEF (%) at:
0 months: 66% (62–73)
During chemotherapy: 58% (50–71)
End of chemotherapy: 51% (28–68)
3/70 patients developed 
severe cardiotoxicity
Tei index is useful 
indicator of 
cardiotoxicity













0 months: 0.45 ± 0.08
12 months: 0.54 ± 0.15, P = 0.0001
LVEF (%) at:
0 months: 64 ± 5 (reference)
12 months: 58 ± 7, P = 0.0001 
0/47 patients had clinical 
signs or symptoms of 
heart failure; 23% were 
reported to have an 
asymptomatic decline 
in LVEF of >10%  
Tei index increased and 
LVEF decreased 
significantly at 12 
months compared to 
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Timing of Tei index 
assessment
Tei index findings and comparison 








Erdogan 2011 (21) 0 and 6 months Tei index for patients:
Baseline: 0.43 ± 0.08
6 months: 0.47 ± 0.07, P = <0.05
Baseline LVEF (%) at:
Baseline: 61.5 ± 5.1
6 months: 61.0 ± 7.2, P > 0.05
8/39 patients developed 
cardiotoxicity at 
follow-up (heart failure 
symptoms)
Tei index is useful 
indicator of cardiotoxicity
Tei index is useful to 
detect chemotherapy-
induced deteriorations 





0 and 6 months Tei index at:
0 month: 0.49 ± 0.09
6 months: 0.54 ± 0.1, P = 0.04
LVEF (%) at:
0 months: 63.0 ± 6.0
6 months: 63.0 ± 5.0, P > 0.05
Not reported Tei index is useful to 
detect chemotherapy 
deteriorations in LV 
function with more 
statistical significance 
than EF
Rohde 2007 (16) 0 months, 
intermediate time 




0 months: 0.42 ± 0.11
Intermediate point: 0.42 ± 0.10,  
P > 0.05
Following last chemotherapy 
cycle: 0.45 ± 0.1
LVEF (%) at:
0 months: 61 ± 6
Intermediate point: not stated
Following last chemotherapy 
cycle: 56% ± 7%, P ≤ 0.001
Not reported Tei index not useful in 
the detection of 
chemotherapy-induced 
deteriorations in LV 
function
Senju 2007 (23) Unclear Tei index at:
0 months: 0.39 ± 0.17 
Follow-up: 0.43 ± 0.18 
(significance not stated)
LVEF (%) at:
0 months: 73.4 ± 9.7
Follow-up: 72.4 ± 12 (significance 
not stated)
No patient developed 
heart failure symptoms
Tei index is not useful in 
the detection of 
chemotherapy-induced 
deteriorations in LV 
function




0 months: 0.59 ± 0.14
Follow-up: 0.66 ± 0.18, P = 0.03
LVEF (%) at:
0 months: 64.5 ± 7.6
Follow-up: 46.9 ± 14.8, P < 0.001
35/80 patients developed 
clinically defined early 
cardiotoxicity and 29/85 
developed heart failure; 
cardiotoxicity with age 
adjusted Δ ejection 
fraction OR 1.12, P < 
0.001, Tei index OR 2.3, 
P = 0.59
Tei index not useful in 
the detection of 
chemotherapy-induced 
deteriorations in LV 
function














0 months, after  













Pulsed wave (PW) Tei index at:
0 months: 0.347 ± 0.115
2–4 cycles: 0.459 ± 0.161
6–8 cycles: 0.424 ± 0.139, 
P = <0.001
Tissue Doppler imaging (TDI) Tei 
index at:
0 months: 0.540 ± 0.107
2–4 cycles: 0.580 ± 0.986
6–8 cycles: 0.560 ± 0.140, P = 0.047
LVEF (%) on echo at:
0 months: 69.0 ± 12.4
2–4 cycles: 68.1 ± 6.6
6–8 cycles: 68.9 ± 7.5, P = 0.785 
24/82 patients had a 
10% decline in LVEF 




impairment (LVEF < 











PW Tei index was a more 
reliable index that TDI  
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P = 0.004) with no significant deterioration seen in the 
breast cancer subgroup (GLS pre-therapy: -16.5±6.5 vs GLS 
post-therapy: −16.3 ± 3.1, P = 0.82). However, the breast 
cancer group did receive a lower dose of anthracyclines 
in comparison to the lymphoma group (168 mg/m2 vs 
346 mg/m2) (18). Shaikh  et al reported that in comparison 
to baseline GLS, there was a significant decline in post 
chemotherapy GLS which was observed in both the 
cardiotoxicity (GLS pre-therapy: −16 ± 3.6 vs GLS post-
therapy: −12.6 ± 3.5, P = 0.001) and non-cardiotoxicity 
groups (GLS pre-therapy −15.7 ± 4.6 vs GLS post-therapy 
−13.6 ± 4.1, P = 0.01) (24).
This review has several limitations including the 
small sample size, which may have led to subclinical 
cardiotoxic event being underestimated. Indeed, there 
are several that did not capture any cardiotoxic events 
(12, 15, 16, 17, 21). Furthermore, there were challenges 
associated with extracting data from studies with variable 
methodology, lack of comparison with LVEF and/or GLS 
and wide ranging definitions of cardiotoxicity.
Several questions remain unanswered regarding the 
role of Tei index in defining and detecting subclinical 
cardiotoxicity. Future studies should look for better ways 
to define an abnormal Tei index value which is sensitive 
and specific in detecting subclinical anthracycline-
induced cardiotoxicity. Additionally, the assessment 
of Tei index in comparison to the parameters currently 
incorporated into international guidelines including LVEF 
(via 2D and 3D assessment) and GLS should be sought.
Conclusion
While there is some evidence to suggest that Tei index 
has value in detecting cardiotoxicity, there is insufficient 
evidence to use it routinely. Furthermore, whether it 
has any advantage over assessment of ejection fraction 
and global longitudinal strain and how it relates to 
cardiotoxicity-related clinical outcomes is an area which 
requires further research.
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